Your browser doesn't support javascript.
loading
Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
Ansari, Marc; Petrykey, Kateryna; Rezgui, Mohamed Aziz; Del Vecchio, Veronica; Cortyl, Jacques; Ralph, Reginald-Olivier; Nava, Tiago; Beaulieu, Patrick; St-Onge, Pascal; Jurkovic Mlakar, Simona; Huezo-Diaz Curtis, Patricia; Uppugunduri, Chakradhara Rao S; Lesne, Laurence; Théoret, Yves; Chalandon, Yves; Bartelink, Imke H; Boelens, Jaap-Jan; Bredius, Robbert G M; Dalle, Jean-Hugues; Lewis, Victor; Kangarloo, Bill S; Peters, Christina; Sinnett, Daniel; Bittencourt, Henrique; Krajinovic, Maja.
Afiliação
  • Ansari M; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Petrykey K; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Rezgui MA; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada.
  • Del Vecchio V; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Cortyl J; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada.
  • Ralph RO; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Nava T; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC)
  • Beaulieu P; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada.
  • St-Onge P; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada.
  • Jurkovic Mlakar S; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Huezo-Diaz Curtis P; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Uppugunduri CRS; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Lesne L; CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Pediatrics, Oncology-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.
  • Théoret Y; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Mon
  • Chalandon Y; Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Bartelink IH; Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Boelens JJ; Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands; Stem Cell Transplantation and Cellular Therapy Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York.
  • Bredius RGM; Department of Pediatrics, Division of Immunology, Infectious Diseases and SCT, Leiden University Medical Center, Leiden, The Netherlands.
  • Dalle JH; Department of Pediatric Hematology and Immunology, Robert Debré Hospital, Assistance Publique, Hôpitaux de Paris and University Paris Diderot, Paris, France.
  • Lewis V; Department of Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Kangarloo BS; Department of Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Peters C; Department of Pediatrics, Stem Cell Transplantation Unit, St Anna Children's Hospital, Vienna, Austria.
  • Sinnett D; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada; Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Bittencourt H; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Mon
  • Krajinovic M; Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, Quebec, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Mon
Biol Blood Marrow Transplant ; 26(5): 920-927, 2020 05.
Article em En | MEDLINE | ID: mdl-31790828
ABSTRACT
Sinusoidal obstruction syndrome (SOS) is a well-recognized and potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). SOS arises from endothelial cell damage and hepatocellular injury mostly due to the transplantation conditioning regimens but also to other patient, disease, and treatment-related factors. Understanding risk factors associated with the development of SOS is critical for early initiation of treatment or prophylaxis. The knowledge about genetic contribution is limited; few studies investigated so far selected a set of genes. To get more comprehensive insight in the genetic component, we performed an exome-wide association study using genetic variants derived from whole-exome sequencing. The analyses were performed in a discovery cohort composed of 87 pediatric patients undergoing HSCT following a busulfan-containing conditioning regimen. Eight lead single-nucleotide polymorphisms (SNPs) were identified after correction for multiple testing and subsequently analyzed in a validation cohort (n = 182). Three SNPs were successfully replicated, including rs17146905 (P = .001), rs16931326 (P = .04), and rs2289971 (P = .03), located respectively in the UGT2B10, BHLHE22, and KIAA1715 genes. UGT2B10 and KIAA1715 were retained in a multivariable model while controlling for nongenetic covariates and previously identified risk variants in the GSTA1 promoter. The modulation of associations by conditioning regimens was noted; KIAA1715 was dependent on the intensity of the conditioning regimen, whereas the effect of UGT2B10 was equally applicable to all of them. Combined effect of associated loci was also observed (P = .00006) with a genotype-related SOS risk of 9.8. To our knowledge, this is the first study addressing the genetic component of SOS at an exome-wide level and identifying novel genetic variations conferring a higher risk of SOS, which might be useful for personalized prevention and treatment strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Veno-Oclusiva / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Veno-Oclusiva / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suíça